NicOx's Naproxcinod: Hitting the NSAID Sweet Spot?
NicOx plans to retain at least some rights to its late-stage osteoarthritis candidate. But can an R&D focused biotech do primary care?
You may also be interested in...
Shares in France's largest biotech, NicOx, received a small boost Dec. 17 after the company reported positive blood pressure data for Phase III-hopeful naproxcinod
NicOx reported positive blood pressure data for Phase III osteoarthritis candidate naproxcinod, but pooled, post-hoc analyses may not be enough to differentiate the drug.
In addition to meeting clinical endpoints, anti-inflammatory continues to show non-detrimental effect on blood pressure.